Validation of the BOADICEA model in a prospective cohort of pathogenic variant carriers.

Date publication

juin 2024

Journal

Journal of medical genetics

Auteurs

Membres identifiés du Cancéropôle Est :
Dr NAMBOT Sophie

Tous les auteurs :
Yang X, Mooij TM, Leslie G, Ficorella L, Andrieu N, Kast K, Singer CF, Jakubowska A, van Gils CH, Tan YY, Engel C, Adank MA, van Asperen CJ, Ausems MGEM, Berthet P, ,Collee MJ, Cook JA, Eason J, Spaendonck-Zwarts KYV, Evans DG, Gómez García EB, Hanson H, Izatt L, Kemp Z, Lalloo F, Lasset C, Lesueur F, Musgrave H, Nambot S, Noguès C, Oosterwijk JC, Stoppa-Lyonnet D, Tischkowitz M, Tripathi V, Wevers MR, Zhao E, van Leeuwen FE, Schmidt MK, Easton DF, Rookus MA, Antoniou AC

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38834293

Résumé

No validation has been conducted for the BOADICEA multifactorial breast cancer risk prediction model specifically in pathogenic variant (PV) carriers to date. Here, we evaluated the performance of BOADICEA in predicting 5-year breast cancer risks in a prospective cohort of PV carriers ascertained through clinical genetic centres.

Mots clés

Early Diagnosis, Genetic Counseling, Public Health, Women's Health

Référence

J Med Genet. 2024 06 4;: